IPO - Profile

Summary

We are a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. We believe our core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 16,800,000 Positive High 18.89%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 22 Jul, 2021

Offer 23 Jul, 2021

Look Ahead

Lock Up Expiry Jan 23, 2022

IPO Terms

Offer Price $17.00
Offer Size 16M

Market Sentiments

Stock Price